NLRP3 and cryopyrin-associated periodic syndrome: While NLRP3 inflammasome is controlled on transcriptional and posttranslational levels and by several endogenous inhibitors and modulators as reviewed by Rathinam and coworkers [21], current therapy of CAPS is based on the broad blockade of IL-1β or IL-1R signaling.